Japanese generics maker eyes Kyorin buyout

Sawai Pharmaceutical (4555.T), one of Japan's top makers of generic drugs, has bought almost five percent of Kyorin (4569.T) and wants to turn the mid-sized drugmaker into a wholly owned unit through a tender offer, the Nikkei reported. Report

Suggested Articles

Teva is reportedly going for a moonshot with a $15 billion drug offer to settle its opioid cases. It's a plan that might just work, one analyst said.

CSL has sued a former exec who its says stole thousands of key documents as he left for competitor Pharming.

Influential U.S. cost watchdog ICER gave its blessing to Johnson & Johnson and Amarin's CV drugs. But there's a big catch for both meds.